https://mindmedicinelaw.com/briefing/integrated-treatment-model-for-opioid-use-schizophrenia-20260603-9788The Psychedelic Journalen2026-06-04T15:05:20.414039+00:00Integrated Treatment Model for Opioid Use & Schizophreniaintegrated treatment model, opioid use disorder, schizophrenia spectrum disorders, dual-diagnosis, clinical outcomes, medication adherence, emergency department visits, healthcare policy, patient engagement, mental healthhttps://mindmedicinelaw.com/briefing/iboga-microdosing-in-tbi-recovery-emerging-evidence-20260603-9801The Psychedelic Journalen2026-06-04T15:04:50.100218+00:00Iboga Microdosing in TBI Recovery: Emerging Evidenceiboga microdosing, traumatic brain injury, hypoxic brain injury, psychedelic therapy, clinical trials, neurological recovery, AEDP, ibogaine, psychedelic research, neurorehabilitationhttps://mindmedicinelaw.com/briefing/fda-accelerates-psychedelics-washington-s-next-steps-20260603-9563The Psychedelic Journalen2026-06-03T15:05:31.227488+00:00FDA Accelerates Psychedelics; Washington's Next StepsFDA, psychedelic research, Washington policy, clinical trials, mental health, drug reclassification, legislative action, Schedule I substances, therapeutic potential, regulatory frameworkshttps://mindmedicinelaw.com/briefing/va-psychedelic-therapy-trial-sparks-missouri-policy-interest-20260603-9564The Psychedelic Journalen2026-06-03T15:05:19.088443+00:00VA Psychedelic Therapy Trial Sparks Missouri Policy InterestVA clinical trial, psychedelic therapy, Missouri policy, veterans mental health, psychedelic-assisted therapy, psilocybin, MDMA, mental health treatment, legislative changes, controlled substanceshttps://mindmedicinelaw.com/briefing/placebo-effects-in-psychedelic-research-implications-for-trials-20260602-9769The Psychedelic Journalen2026-06-04T15:05:07.938325+00:00Placebo Effects in Psychedelic Research: Implications for Trialsplacebo effects, psychedelic research, clinical trials, contextual influence, altered states of consciousness, ego dissolution, nocebo effects, set and setting, trait responsiveness, therapeutic applicationshttps://mindmedicinelaw.com/briefing/european-consensus-on-trlld-framework-for-future-research-20260602-9813The Psychedelic Journalen2026-06-04T15:04:58.979987+00:00European Consensus on TRLLD: Framework for Future Researchtreatment-resistant late-life depression, TRLLD, European task force, Delphi process, depression in elderly, clinical guidelines, operational staging model, decision-making algorithm, psychiatric research, mental health policyhttps://mindmedicinelaw.com/briefing/esketamine-and-psychotherapy-promising-combo-for-trd-20260602-9812The Psychedelic Journalen2026-06-04T15:04:27.391611+00:00Esketamine and Psychotherapy: Promising Combo for TRDesketamine, psychotherapy, treatment-resistant depression, ketamine-assisted psychotherapy, clinical trial, mental health treatment, neuroplasticity, pharmacological effects, emotional processing, integrated treatmenthttps://mindmedicinelaw.com/briefing/at-home-ketamine-therapy-for-grief-real-world-insights-20260602-9482The Psychedelic Journalen2026-06-03T15:06:14.324430+00:00At-Home Ketamine Therapy for Grief: Real-World Insightsketamine-assisted therapy, prolonged grief, at-home psychedelic therapy, real-world study, mental health treatment, psychedelic researchhttps://mindmedicinelaw.com/briefing/plant-metabolites-in-sud-treatment-neuropharmacology-insights-20260602-9484The Psychedelic Journalen2026-06-03T15:06:03.983265+00:00Plant Metabolites in SUD Treatment: Neuropharmacology Insightsplant metabolites, substance use disorders, neurotransmission, bioavailability, clinical validation, monoaminergic systems, personalized medicine, pharmacotherapy, neuropharmacology, essential oilshttps://mindmedicinelaw.com/briefing/psychedelic-assisted-therapies-in-palliative-care-current-insights-20260602-9483The Psychedelic Journalen2026-06-03T15:05:40.091232+00:00Psychedelic-Assisted Therapies in Palliative Care: Current Insightspsychedelic-assisted therapies, palliative care, ketamine-assisted psychotherapy, clinical trials, existential distress, oncology populations, therapeutic protocols, psychological suffering, spiritual well-being, safety profileshttps://mindmedicinelaw.com/briefing/enhancing-ketamine-therapy-neuroplasticity-and-behavioral-methods-20260602-9403The Psychedelic Journalen2026-06-02T22:03:51.820196+00:00Enhancing Ketamine Therapy: Neuroplasticity and Behavioral Methodsketamine therapy, neuroplasticity, behavioral therapy, nonpharmacological methods, clinical trials, mental healthhttps://mindmedicinelaw.com/briefing/fda-s-approach-to-open-label-psychedelic-trials-20260602-9401The Psychedelic Journalen2026-06-02T22:03:42.324234+00:00FDA's Approach to Open-Label Psychedelic TrialsFDA, open-label trials, psychedelic research, clinical trials, efficacy evaluation, safety assessment, trial design, regulatory guidelines, placebo effect, psychedelic therapieshttps://mindmedicinelaw.com/briefing/esketamine-s-role-in-reducing-postoperative-anxiety-in-adolescents-20260601-9818The Psychedelic Journalen2026-06-04T15:04:39.998171+00:00Esketamine's Role in Reducing Postoperative Anxiety in Adolescentsesketamine, postoperative anxiety, adolescents, randomized controlled trial, perioperative care, psychological distresshttps://mindmedicinelaw.com/briefing/bdnf-as-a-biomarker-in-depression-treatment-20260601-9497The Psychedelic Journalen2026-06-03T22:04:08.593148+00:00BDNF as a Biomarker in Depression Treatmentbdnf, depression, biomarker, personalized medicine, neuroplasticity, mental health, genetic polymorphisms, epigenetic changes, treatment response, neurotrophic factorhttps://mindmedicinelaw.com/briefing/ketamine-in-hip-arthroplasty-clinical-review-insights-20260601-9538The Psychedelic Journalen2026-06-03T22:03:55.144702+00:00Ketamine in Hip Arthroplasty: Clinical Review Insightsketamine, hip arthroplasty, systematic review, pain management, clinical guidelines, anesthetic, analgesic, surgical settings, NMDA receptor, opioid consumptionhttps://mindmedicinelaw.com/briefing/ibogaine-research-30-years-of-study-and-ongoing-challenges-20260601-9485The Psychedelic Journalen2026-06-03T15:05:51.232745+00:00Ibogaine Research: 30 Years of Study and Ongoing Challengesibogaine research, substance use disorders, psychedelic therapies, clinical trials, cardiotoxicity, psychiatric carehttps://mindmedicinelaw.com/briefing/ketamine-infusion-alters-drug-clearance-clinical-implications-20260601-9395The Psychedelic Journalen2026-06-02T22:04:13.639773+00:00Ketamine Infusion Alters Drug Clearance: Clinical Implicationsketamine infusion, drug clearance, tacrolimus, sirolimus, drug interactions, clinical implications, pharmacokinetics, immunosuppressants, patient safety, treatment protocolshttps://mindmedicinelaw.com/briefing/melsmon-s-potential-in-reducing-neuroinflammation-in-depression-20260601-9176The Psychedelic Journalen2026-06-02T22:04:02.400924+00:00Melsmon's Potential in Reducing Neuroinflammation in DepressionMelsmon, neuroinflammation, depression, HPA axis, placental extract, preclinical study, stress-related disorders, mouse model, cytokines, therapeutic strategyhttps://mindmedicinelaw.com/briefing/us-psychedelic-facilitation-training-current-analysis-and-implications-20260529-9557The Psychedelic Journalen2026-06-03T22:04:18.892230+00:00US Psychedelic Facilitation Training: Current Analysis and Implicationspsychedelic facilitation, training programs, US policy, clinical practice, public health, psychedelic therapy, facilitator accreditation, therapeutic outcomes, risk management, psychedelic researchhttps://mindmedicinelaw.com/briefing/ketamine-trials-and-personalized-antipsychotic-use-clinical-insights-20260526-8222The Psychedelic Journalen2026-06-02T22:04:34.653488+00:00Ketamine Trials and Personalized Antipsychotic Use: Clinical Insightsketamine trials, personalized medicine, antipsychotic selection, treatment-resistant schizophrenia, insomnia medication abuse, cognitive interventionshttps://mindmedicinelaw.com/briefing/childhood-as-a-model-for-understanding-psychedelic-effects-20260526-8575The Psychedelic Journalen2026-06-02T22:04:23.367633+00:00Childhood as a Model for Understanding Psychedelic Effectsneural plasticity, childhood development, psychedelic effects, therapeutic applications, cognitive development, psychedelic research, clinical practice, policy implications, neurosciencehttps://mindmedicinelaw.com/briefing/vagal-afferents-in-epilepsy-mechanisms-and-implications-20260525-7904The Psychedelic Journalen2026-06-03T22:04:36.567305+00:00Vagal Afferents in Epilepsy: Mechanisms and Implicationsvagal nerve stimulation, epilepsy treatment, neuroscience, clinical trials, vagal afferents, neuromodulation, temporal lobe epilepsy, VGluT2-positive afferentshttps://mindmedicinelaw.com/briefing/psilocybin-s-effects-on-planarian-behavior-insights-for-human-trials-20260525-8581The Psychedelic Journalen2026-06-03T22:04:29.153626+00:00Psilocybin's Effects on Planarian Behavior: Insights for Human Trialspsilocybin, planarian behavior, serotonin pathways, neuropharmacology, clinical trials, psychiatric disorders, therapeutic applications, psychedelic research, human trials, neurosciencehttps://mindmedicinelaw.com/briefing/swiss-survey-reveals-psychedelic-therapy-methods-20260520-8117The Psychedelic Journalen2026-06-03T22:04:44.548726+00:00Swiss Survey Reveals Psychedelic Therapy Methodspsychedelic therapy, Swiss physicians, clinical methods, standardized protocols, patient safety, international guidelines, training programs, treatment efficacy, policy implications, research directions